Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer

Hylander, Bonnie; Repasky, Elizabeth A.; Shrikant, Protul; Intengan, Marilyn; Beck, Amy; Driscoll, Deborah L.; Singhal, Pankaj; Lele, Shashikant; Odunsi, Kunle

doi:10.1016/j.ygyno.2005.09.052

Cited by 78 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of immunohistochemical detection of WT1 protein expression in OSA was 83.2% (99 of 119 Other abbreviations as in Tables 2 to 3 RR Relative risk, CI confidence interval a Mean values cases), which was compatible with the range reported in previous studies (50.5-97%) [1,13]. The introduction of TMA technology allowed a large number of specimens to be processed and was especially useful for comparative scoring of WT1 protein expression with specimens subjected to IHC under identical conditions.…”

Section: Discussionsupporting

confidence: 85%

“…Such oncogenes and oncogene products may be of a clinical utility as predictive or prognostic factors and as therapeutic targets. So far, it has been shown that the incidence of WT1-positive tumors was highest in OSA among the various histological types of ovarian carcinoma [1,13]. However, there is limited evidence for the clinicopathologic significance of WT1 in ovarian carcinomas [13,21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma

et al. 2007

View full text Add to dashboard Cite

Recently, oncogenic potential of the WT1 gene has been proposed in some human solid tumors and leukemias. Although previous studies have shown the frequent expression of the WT1 protein in ovarian serous adenocarcinomas (OSAs), its clinicopathologic significance is still unclear. We immunohistochemically examined the expression status of WT1 in 119 OSAs and analyzed the correlation of the intensity of WT1 immunoreactivity with the level of WT1 mRNA expression by quantitative real-time polymerase chain reaction, clinicopathologic variables, expression of p53, Bcl-2, and Ki-67 labeling index (LI). Of 119 OSAs, nuclear WT1 immunoreactivity was positive in 99 (83%), of which 44 (44%) and 55 (56%) exhibited high and low WT1 immunoreactivities, respectively. The quantitative WT1 mRNA levels were significantly correlated with the intensity of WT1 immunoreactivity (P < 0.05). In comparison with WT1-negative OSAs, the WT1-positive OSAs showed a higher grade (P = 0.007), advanced stage (P = 0.018), and higher Ki-67 LI (P < 0.001). Additionally, high WT1 immunoreactivity was correlated with a higher grade (P = 0.003), Ki-67 LI (P = 0.012), Bcl-2 expression (P = 0.003), and poorer patient outcome (5-year survival, 36.5 vs 63.8%, P = 0.008 by log-rank test). The WT1 protein may be an accelerator of the progression of OSA.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Sera et al found that over expressed WT1 was associated with tumor growth and resulted in worse prognosis of hepatocellular carcinoma (Sera et al, 2008). Hylander et al showed that patients with WT1-positive tumors had a higher grade (p=0.006) and advanced stage (p=0.002) of epithelial ovarian cancer (Hylander B et al, 2006). Miyoshi et al concluded that tumors >2 cm also demonstrated an orientation toward a rise (p=0.09) in WT1 (Miyoshi et al, 2002b).…”

Section: Discussionmentioning

confidence: 99%

Wilms' Tumor Gene (WT1) Expression Correlates with Vascular Epithelial Growth Factor (VEGF) in Newly Acute Leukemia Patients Undergoing Chemotherapy

Iranparast¹,

Assarehzadegan²,

Heike³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Today, leukemia is one of the biggest problems worldwide. The Wilms' tumor gene (WT1) and the vascular endothelial growth factor (VEGF) gene are highly expressed in patients with various cancers. This study concerned the relationship between expression of WT1 and VEGF in patients with acute leukemia. Materials and Methods: We evaluated expression of WT1 mRNA and VEGF mRNA using real-time quantitative RT-PCR in the peripheral blood (PB) of 8 newly diagnosed AML and 4 newly diagnosed ALL patients, serially monitored for 2 months. A further 12 normal PB samples served as controls. Results: In the patient group, in comparison with the normal ranges, WT1 and VEGF gene expression was increased, the average values for the expression of these two genes being 0.2852±0.11 and 0.2029±0.018, respectively. While was no significant relevance between the two genes pre-treatment, a positive link between the two genes in 75% of patients with AML was noted during the procedure of chemotherapy, whereas in 75% of patients with ALL an antiparallel association was observed. Conclusions: Leukemia is associated with production of WT1, which may affect the expression of VEGF.

show abstract

“…However, in an immunohistochemical work up of a carcinoma of unknown primary in an adult, WT1 is considered to be a highly sensitive and specific marker of mullerian serous carcinoma of ovarian, tubal, or primary peritoneal origin. [4][5][6][7] It is also highly expressed in normal and malignant mesothelium. 8 Overexpression of WT1 mRNA in different types of hematological malignancies and solid tumors has been observed in recent studies.…”

mentioning

confidence: 99%

WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes

et al. 2008

View full text Add to dashboard Cite

Current literature suggests that strong WT1 expression in a carcinoma of unknown origin virtually excludes a breast primary. Our previous pilot study on WT1 expression in breast carcinomas has shown WT1 expression in approximately 10% of carcinomas that show mixed micropapillary and mucinous morphology (Mod Pathol 2007;20(Suppl 2):38A). To definitively assess as to what subtype of breast carcinoma might express WT1 protein, we examined 153 cases of invasive breast carcinomas. These consisted of 63 consecutive carcinomas (contained 1 mucinous tumor), 20 cases with micropapillary morphology (12 pure and 8 mixed), 6 micropapillary 'mimics' (ductal no special type carcinomas with retraction artifacts), 33 pure mucinous carcinomas and 31 mixed mucinous carcinomas (mucinous mixed with other morphologic types). Overall, WT1 expression was identified in 33 carcinomas, that is, 22 of 34 (65%) pure mucinous carcinomas and in 11 of 33 (33%) mixed mucinous carcinomas. The non-mucinous component in these 11 mixed mucinous carcinomas was either a ductal no special type carcinoma (8 cases) or a micropapillary component (3 cases). WT1 expression level was similar in both the mucinous and the non-mucinous components. The degree of WT1 expression was generally weak to moderate (490% cases) and rarely strong (o10% cases). None of the breast carcinoma subtype unassociated with mucinous component showed WT1 expression.

show abstract

Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer

Cited by 78 publications

References 14 publications

Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma

Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma

Wilms' Tumor Gene (WT1) Expression Correlates with Vascular Epithelial Growth Factor (VEGF) in Newly Acute Leukemia Patients Undergoing Chemotherapy

WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes

Contact Info

Product

Resources

About